Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226700 · ClinicalTrials.gov registry record · Phase 3
Suzetrigine in Total Hip Arthroplasty
A Phase 3 study of Pain and Pain Management, sponsored by Hospital for Special Surgery, New York.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 210
- Enrollment target
- 1
- Study location
NCT07226700: Recruiting Phase 3 study of Pain and Pain Management, sponsored by Hospital for Special Surgery, New York.
NCT07226700 is a Phase 3 study of Pain and Pain Management that is actively recruiting participants, run by Hospital for Special Surgery, New York. The registered enrollment target is 210 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (31% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07226700, a Phase 3 study of Pain and Pain Management, is actively recruiting participants, sponsored by Hospital for Special Surgery, New York.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 210 participants
- Enrollment target
- 1
- Study location
Study Summary
Total hip and knee joint replacements are among the most common and painful orthopedic procedures performed worldwide, often requiring intensive analgesia to support early ambulation and recovery. Despite widespread use of multimodal regimens, many patients still rely on opioids, which can cause sedation, nausea, constipation, and long-term dependency. Evaluating Suzetrigine in this high-need population may improve recovery trajectories, reduce opioid consumption, and support enhanced recovery protocols. Given the growing surgical volume and the emphasis on opioid-sparing strategies, rigorous investigation of Suzetrigine's efficacy in joint replacement is of high clinical value. In this study, patients undergoing primary total hip replacement will be randomized to receive either Suzetrigine or placebo for seven days, with the loading dose administered prior to surgery. The primary outcome is cumulative 48-hour opioid consumption in oral morphine equivalents starting from entry into the post-anesthesia care unit (PACU).
Primary Outcome
The primary outcome is cumulative 48-hour opioid consumption in oral morphine equivalents starting from entry into the post-anesthesia care unit (PACU). This measure will be taken from EPIC via the MAR and documented in the study "MUD"; post-discharge, patient to report date/time of opioid use # of pills, dose in diary and documented in study "MUD". Measurements will be taken in PACU and 0-48 hrs following surgery.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Suzetrigine
Study Locations (1)
New York
- Hospital for Special Surgery - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2028-11-01 |
| Phase | Phase 3 |
What NCT07226700 shows while recruiting
NCT07226700 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, below the 304-participant average among 374 other Pain trials with a reported enrollment target (31% lower).
The record links to 9 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07226700 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07226700 about?
NCT07226700 is a clinical study titled "Suzetrigine in Total Hip Arthroplasty". Total hip and knee joint replacements are among the most common and painful orthopedic procedures performed worldwide, often requiring intensive analgesia to support early ambulation and recovery. Despite widespread use of multimodal regimens, many patients still rely on opioids, which can cause sed...
What is the current status of trial NCT07226700?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 210 participants. The study started on 2025-11-03. Estimated completion is 2028-11-01.
What conditions does trial NCT07226700 study?
This clinical trial studies the following conditions: Pain, Pain Management, Total Hip Arthroplasty (THA), Total Hip Replacement, Total Hip Replacement Surgery.
What interventions are being tested in trial NCT07226700?
The interventions under investigation include: Placebo (OTHER), Suzetrigine (DRUG).
Who is sponsoring clinical trial NCT07226700?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226700 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07226700's enrollment target sits among peer trials
210 85th of 374 higher than 290 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures: A Pragmatic, Randomized Controlled Trial
RECRUITING · Phase 3
-
Opioid-Free Orthopaedics
RECRUITING · Phase 3
-
Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits
RECRUITING · Phase 3
-
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
RECRUITING · Phase 3
-
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
RECRUITING · Phase 3
-
Protocolized vs Discretionary Use of Opioids in Acute Pain
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI